The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review

Background In the absence of highly effective antiviral therapies against SARS-CoV-2, it is crucial to counter the known pathophysiological causes of severe COVID-19. Evaluating the efficacy existing drugs may expedite the development of such therapeutics. Severe COVID-19 is largely the result of a...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	PeerJ
المؤلفون الرئيسيون:	Avi Gurion Kaye, Robert Siegel
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	PeerJ Inc. 2020-11-01
الموضوعات:	COVID-19 Tocilizumab IL-6 SARS-COV-2
الوصول للمادة أونلاين:	https://peerj.com/articles/10322.pdf

مواد مشابهة

Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy
حسب: David Beauvais, وآخرون
منشور في: (2021-04-01)

Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia
حسب: Daria Fomina, وآخرون
منشور في: (2020-10-01)

A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages
حسب: Maaike C. Swets, وآخرون
منشور في: (2023-04-01)

Evaluating the efficacy of different doses of tocilizumab in treating critically ill COVID–19 patients: a single–center retrospective cohort study
حسب: Jie Gao, وآخرون
منشور في: (2025-07-01)

Tocilizumab binds to canine IL-6 receptor and elicits in-vitro inhibitory biological response
حسب: Yael Merbl, وآخرون
منشور في: (2025-09-01)

Prognostic significance of serum interleukin-6 in severe/critical COVID-19 patients treated with tocilizumab: a detailed observational study analysis
حسب: Panpan Liang, وآخرون
منشور في: (2024-11-01)

Efficacy of Tocilizumab in Patients with a Moderate and Severe COVID-19: A Retrospective Single Center Cohort Study
حسب: Sibel BOLUKÇU, وآخرون
منشور في: (2021-01-01)

Influence of anti-Spike protein antibody levels on tocilizumab efficacy in hospitalized patients with severe COVID-19 pneumonia: a post-hoc analysis of the COVACTA trial
حسب: José Aguareles, وآخرون
منشور في: (2025-05-01)

Tocilizumab for Severe COVID-19 Infection and Multisystem Inflammatory Syndrome in Adults and Children
حسب: Amber N. Edinoff, وآخرون
منشور في: (2023-03-01)

Efficacy of Tocilizumab in Patients with COVID-19
حسب: Ahmad Alikhani, وآخرون
منشور في: (2022-12-01)

Effect of Tocilizumab Treatment on Seroconversion in Hyperinflammation Secondary to Covid 19
حسب: Nilgün Işıksaçan, وآخرون
منشور في: (2024-04-01)

Incidence of secondary bacterial infections following utilization of tocilizumab for the treatment of COVID-19 – A matched retrospective cohort study
حسب: Joanna L Moore, وآخرون
منشور في: (2021-01-01)

Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis
حسب: Sakkas LI
منشور في: (2016-08-01)

Why tocilizumab could be an effective treatment for severe COVID-19?
حسب: Binqing Fu, وآخرون
منشور في: (2020-04-01)

Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19
حسب: Nastaran Injinari, وآخرون
منشور في: (2024-10-01)

Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes
حسب: Abeer Al-Baadani, وآخرون
منشور في: (2021-08-01)

Current concepts of tocilizumab efficacy in active moderate-to-severe corticosteroid-resistant cases of Graves’ orbitopathy
حسب: Georgios Boutzios, وآخرون
منشور في: (2025-09-01)

EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY
حسب: T. V. Beketova, وآخرون
منشور في: (2018-05-01)

Tocilizumab is associated with reduced delirium and coma in critically ill patients with COVID-19
حسب: Tuqa Alkhateeb, وآخرون
منشور في: (2024-05-01)

Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study
حسب: Tariq Kewan, وآخرون
منشور في: (2020-07-01)

Tocilizumab in combination with corticosteroids: potential for managing cancer cachexia with systemic hyperinflammation
حسب: Ping Chen, وآخرون
منشور في: (2024-12-01)

A spectacular effect of tocilizumab in Takayasu arteritis
حسب: Fatma Saïd, وآخرون
منشور في: (2024-11-01)

Positive outcome of a twin pregnancy after the administration of tocilizumab to a pregnant woman with severe COVID-19
حسب: Dickov Isidora, وآخرون
منشور في: (2024-01-01)

Tocilizumab effectively reduces flares of hyperimmunoglobulin D syndrome in children: Three cases in China
حسب: Chenxi Li, وآخرون
منشور في: (2024-09-01)

Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation during Acute Respiratory Distress: A Case Report and Literature Review
حسب: Faryal Farooqi, وآخرون
منشور في: (2020-07-01)

Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study
حسب: Yanxin Chen, وآخرون
منشور في: (2025-01-01)

Tocilizumab for Non-Infectious Uveitis: A Systematic Review
حسب: Cao H, وآخرون
منشور في: (2025-09-01)

Association of Polymorphisms of IL-6 Pathway Genes (IL6, IL6R and IL6ST) with COVID-19 Severity in an Amazonian Population
حسب: Fabíola Brasil Barbosa Rodrigues, وآخرون
منشور في: (2023-05-01)

IL-6/IL-6R Signaling Blockade Alleviates Chronic Allograft Rejection by Modulating Germinal Center B Cells and Allograft Inflammation in Murine Cardiac Transplantation
حسب: Xia R, وآخرون
منشور في: (2025-07-01)

Role of <i>IL6R</i> Genetic Variants in Predicting Response to Tocilizumab in Patients with Rheumatoid Arthritis
حسب: Luis Sainz, وآخرون
منشور في: (2022-09-01)

Prevention of bleomycin-induced pulmonary fibrosis by vaccination with the Tocilizumab mimotope
حسب: Jin Guo, وآخرون
منشور في: (2024-12-01)

Tocilizumab prescribing criteria for COVID-19 patients
حسب: Ayman M. Al-Qaaneh, وآخرون
منشور في: (2021-04-01)

Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial
حسب: Tomohiro Koga, وآخرون
منشور في: (2018-12-01)

Navigating therapeutic challenges in VEXAS syndrome: exploring IL-6 and JAK inhibitors at the forefront
حسب: Xiao Xiao Li, وآخرون
منشور في: (2024-09-01)

Tocilizumab in Combination with Corticosteroids in COVID-19 Pneumonia: A Single-Centre Retrospective Controlled Study
حسب: Zsófia Kardos, وآخرون
منشور في: (2023-01-01)

Tocilizumab Contributes to the Inflammatory Status of Mature Dendritic Cells through Interleukin-6 Receptor Subunits Modulation
حسب: Daniel Meley, وآخرون
منشور في: (2017-08-01)

IL-6R Inhibitors and Gastrointestinal Perforations: A Pharmacovigilance Study and a Predicting Nomogram
حسب: Shupeng Zou, وآخرون
منشور في: (2024-12-01)

INNOVATIVE TREATMENTS FOR TAKAYASU’S ARTERITIS: A FOCUS ON INTERLEUKIN-6 INHIBITORS. THE AUTHORS’ EXPERIENCE WITH TOCILIZUMAB AND A REVIEW OF LITERATURE
حسب: T. V. Beketova, وآخرون
منشور في: (2017-10-01)

Tocilizumab therapy for IL-6 increment in a patient with non-fatal severe fever with thrombocytopenia syndrome
حسب: Jeong Rae Yoo, وآخرون
منشور في: (2022-09-01)

SEVERE HYPOFIBRINOGENEMIA IN A PATIENT WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB: CASE-BASED REVIEW
حسب: Željka Kardum, وآخرون
منشور في: (2023-12-01)